Enhancer of zeste homolog 2 (EZH2)-dependent sirtuin-3 determines sensitivity to glucose starvation in radioresistant head and neck cancer cells

被引:0
|
作者
Chang, Hyo Won [1 ]
Park, Jung Je [2 ]
Lee, Won Hyeok [3 ]
Kim, Song Hee [3 ]
Lee, Jong Cheol [4 ]
Nam, Hae Yun [1 ]
Kim, Mi Ra [4 ]
Han, Myung Woul [3 ]
Lee, Yoon Se [5 ]
Kim, Sang Yoon [6 ]
Kim, Seong Who [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biochem & Mol Biol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
[2] Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Otolaryngol, Jinju, South Korea
[3] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Otolaryngol, Ulsan, South Korea
[4] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Otolaryngol, Kangnung, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea
[6] Pharosgen Co Ltd, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
EZH2; SIRT3; Glucose starvation; Head and neck cancer cell; Radioresistance; OXIDATIVE STRESS; BREAST-CANCER; STEM-CELLS; EZH2; SIRT3; INHIBITION; MECHANISMS; GENE; CONTRIBUTES; DEFICIENCY;
D O I
10.1016/j.cellsig.2023.111029
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Sirtuin 3 (SIRT3) regulates mitochondrial function as a mitochondrial deacetylase during oxidative stress. However, the specific regulatory mechanism and function of SIRT3 in radioresistant cancer cells are unclear. In this study, we aim to investigate how SIRT3 determines the susceptibility to glucose deprivation and its regulation in p53-based radioresistant head and neck cancer cells. We observed mitochondrial function using two established isogenic radioresistant subclones (HN3R-A [p53 null] and HN3R-B [p53 R282W]) with intratumoral p53 heterogeneity. Cell counting analysis was performed to evaluate cell proliferation and cell death. The correlation between the regulation of SIRT3 and enhancer of zeste homolog 2 (EZH2) was confirmed by immunoblotting and chromatin immunoprecipitation assay. p53-deficient radioresistant cells (HN3R-A) expression reduced SIRT3 levels and increased sensitivity to glucose deprivation due to mitochondrial dysfunction compared to other cells. In these cells, activation of SIRT3 significantly prevented glucose deprivation-induced cell death, whereas the loss of SIRT3 increased the susceptibility to glucose deficiency. We discovered that radiation-induced EZH2 directly binds to the SIRT3 promoter and represses the expression. Conversely, inhibiting EZH2 increased the expression of SIRT3 through epigenetic changes. Our findings indicate that p53 -deficient radioresistant cells with enhanced EZH2 exhibit increased sensitivity to glucose deprivation due to SIRT3 suppression. The regulation of SIRT3 by EZH2 plays a critical role in determining the cell response to glucose deficiency in radioresistant cancer cells. Therefore, EZH2-dependent SIRT3 could be used as a predictive biomarker to select treatment options for patients with radiation-resistance.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Positive Expression of Enhancer of Zeste Homolog 2 (EZH2) Predicts Shorter Overall Survival in Patients with Inflammatory Breast Cancer
    Gong, Y.
    Huo, L.
    Sneige, N.
    Cristofanilli, M.
    LABORATORY INVESTIGATION, 2010, 90 : 47A - 48A
  • [22] Enhancer of zeste homolog 2 (EZH2) gene inhibition via 3-Deazaneplanocin A (DZNep) in human liver cells and it is relation with fibrosis
    Ozel, Merve
    Guven, Ilker
    Kilic, Eser
    Dundar, Munis
    Baskol, Gulden
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2020, 45 (06): : 737 - 745
  • [23] Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) is associated with cancer metastasis and poor prognosis in breast cancer
    Guo, Yawen
    Maimaiti, Yusufu
    Yu, Pan
    Liu, Zeming
    Chen, Chen
    Zhang, Yunke
    Yin, Xingjie
    Wang, Shan
    Xiu, Nie
    Bangxing, Huang
    Liu, Chunping
    Huang, Tao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 2672 - 2683
  • [24] Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells
    Bugide, Suresh
    Green, Michael R.
    Wajapeyee, Narendra
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (15) : E3509 - E3518
  • [25] High glucose-stimulated enhancer of zeste homolog-2 (EZH2) forces suppression of deptor to cause glomerular mesangial cell pathology
    Das, Falguni
    Bera, Amit
    Ghosh-Choudhury, Nandini
    Sataranatarajan, Kavitha
    Kamat, Amrita
    Kasinath, Balakuntalam S.
    Choudhury, Goutam Ghosh
    CELLULAR SIGNALLING, 2021, 86
  • [26] ENHANCER OF ZESTE HOMOLOG 2 (EZH2) IS A POWERFUL INDEPENDENT PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA AND CONTRIBUTES TO CELL PROLIFERATION AND APOPTOSIS RESISTANCE IN RENAL CANCER CELLS
    Wagener, N.
    Macher-Goeppinger, S.
    Holland, D.
    Cmkovic-Mertens, I.
    Hoppe-Seyler, K.
    Pritsch, M.
    Haferkamp, A.
    Schirmacher, P.
    Hoppe-Seyler, F.
    Hohenfellner, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 193 - 193
  • [27] Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells
    Boehm, Julian
    Muenzner, Julienne Kathrin
    Caliskan, Aylin
    Ndreshkjana, Benardina
    Erlenbach-Wuensch, Katharina
    Merkel, Susanne
    Croner, Roland
    Rau, Tilman T.
    Geppert, Carol Immanuel
    Hartmann, Arndt
    Roehe, Adriana Vial
    Schneider-Stock, Regine
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (09) : 2227 - 2240
  • [28] Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells
    Julian Böhm
    Julienne Kathrin Muenzner
    Aylin Caliskan
    Benardina Ndreshkjana
    Katharina Erlenbach-Wünsch
    Susanne Merkel
    Roland Croner
    Tilman T. Rau
    Carol Immanuel Geppert
    Arndt Hartmann
    Adriana Vial Roehe
    Regine Schneider-Stock
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 2227 - 2240
  • [29] Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients
    Ogata, R
    Matsueda, S
    Yao, A
    Noguchi, M
    Itoh, K
    Harada, M
    PROSTATE, 2004, 60 (04): : 273 - 281
  • [30] Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines
    Eskander, Ramez N.
    Ji, Tao
    Huynh, Be
    Wardeh, Rooba
    Randall, Leslie M.
    Hoang, Bang
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (06) : 997 - 1005